Izalontamab (5-46 mg/kg; i.v., every 7 days once, 4 doses in total) shows different anti-tumor efficacy in different types of tumors[1].
| Animal Model: | Female NOD/SCID mouse with SW48, FaDu and KYSE-150 xenografts[1] |
| Dosage: | 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150) |
| Administration: | Intravenous injection; 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150); every 7 days once, 4 doses in total |
| Result: | Dose-dependently inhibited the growth of FaDu and KYSE-150 tumors at the dose of 10 mg/kg. Inhibited 63.6% SW48 tumor growth at the dose of 46 mg/kg.
|
